Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Regulatory
152 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Tucatinib | EU EMA | Malignant Breast Neoplasm | Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2?positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens. | approved | Feb 11, 2021 | ema |
| Tucatinib | US FDA | HER2-Positive Breast Carcinoma | in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. | approved | Apr 17, 2020 | openfda |
Data updated 11 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Trastuzumab | 72 | 37 | 35 |
| Lapatinib | 44 | 28 | 16 |
| Fulvestrant | 34 | 29 | 5 |
| Palbociclib | 33 | 29 | 4 |
| Neratinib | 24 | 22 | 2 |
| Tamoxifen | 19 | 11 | 8 |
| Dactolisib | 18 | 10 | 8 |
| Pictilisib | 15 | 14 | 1 |
| Trastuzumab Emtansine | 14 | 5 | 9 |
| Alpelisib | 12 | 8 | 4 |
| Olaparib | 10 | 7 | 3 |
| Afatinib | 9 | 8 | 1 |
| PI3Ka/Di | 9 |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 7 |
| 2 |
| Capecitabine | 8 | 7 | 1 |
| Everolimus | 8 | 7 | 1 |
| Inavolisib | 8 | 8 | 0 |
| Bevacizumab | 7 | 6 | 1 |
| PI-103 | 7 | 5 | 2 |
| Capivasertib | 6 | 6 | 0 |
| Sirolimus | 6 | 2 | 4 |
| Dovitinib | 5 | 5 | 0 |
| Hormone Therapy | 5 | 0 | 5 |
| Cisplatin | 4 | 4 | 0 |
| Doxorubicin | 4 | 4 | 0 |
| Exemestane | 4 | 4 | 0 |
| Letrozole | 4 | 3 | 1 |
| MTOR Kinase Inhibitor PP242 | 4 | 4 | 0 |
| Sunitinib | 4 | 4 | 0 |
| Talazoparib | 4 | 4 | 0 |
| Akt Inhibitor MK2206 | 3 | 2 | 1 |
| Carboplatin | 3 | 3 | 0 |
| Cetuximab | 3 | 3 | 0 |
| Crizotinib | 3 | 3 | 0 |
| Lucitanib | 3 | 3 | 0 |
| Paclitaxel | 3 | 0 | 3 |
| RapaLink-1 | 3 | 1 | 2 |
| Ribociclib | 3 | 1 | 2 |
| Aromatase Inhibitor | 2 | 1 | 1 |
| CDK Inhibitor SNS-032 | 2 | 2 | 0 |
| Dasatinib | 2 | 2 | 0 |
| Docetaxel | 2 | 2 | 0 |
| Erdafitinib | 2 | 2 | 0 |
| Futibatinib | 2 | 2 | 0 |
| Imlunestrant Regimen | 2 | 2 | 0 |
| Immune Checkpoint Inhibitor | 2 | 1 | 0 |
| Izorlisib | 2 | 2 | 0 |
| MTOR Kinase Inhibitor AZD8055 | 2 | 0 | 2 |
| Pan-AKT Kinase Inhibitor GSK690693 | 2 | 1 | 1 |
| Pazopanib | 2 | 2 | 0 |
| Pertuzumab | 2 | 2 | 0 |
| Phosphatidylinositide 3-Kinase Inhibitor | 2 | 2 | 0 |
| Pidnarulex | 2 | 2 | 0 |
| Quarfloxin | 2 | 2 | 0 |
| Rogaratinib | 2 | 2 | 0 |
| Sacituzumab Govitecan | 2 | 0 | 2 |
| Selective Estrogen Receptor Covalent Antagonist H3B-6545 | 2 | 2 | 0 |
| Spliceostatin A | 2 | 2 | 0 |
| A66 | 1 | 1 | 0 |
| Abemaciclib Regimen | 1 | 1 | 0 |
| Afimoxifene | 1 | 0 | 1 |
| AKTi-1/2 | 1 | 1 | 0 |
| Aminoglutethimide | 1 | 1 | 0 |
| Bazedoxifene | 1 | 1 | 0 |
| Bortezomib | 1 | 1 | 0 |
| Canertinib | 1 | 1 | 0 |
| CDK4/6 Inhibition | 1 | 0 | 1 |
| Checkpoint Kinase Inhibitor AZD7762 | 1 | 1 | 0 |
| Disitamab Vedotin | 1 | 1 | 0 |
| Durvalumab | 1 | 1 | 0 |
| Elacestrant | 1 | 1 | 0 |
| Endocrine Drug Therapy | 1 | 1 | 0 |
| Epirubicin | 1 | 1 | 0 |
| Erdafitinib Regimen | 1 | 1 | 0 |
| Eribulin | 1 | 1 | 0 |
| Everolimus/Exemestane Regimen | 1 | 1 | 0 |
| FAC Regimen | 1 | 0 | 1 |
| FEC Regimen | 1 | 0 | 1 |
| FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 | 1 | 1 | 0 |
| Foretinib | 1 | 1 | 0 |
| Gemcitabine | 1 | 1 | 0 |
| GF109203X | 1 | 1 | 0 |
| Go6983 | 1 | 1 | 0 |
| Imatinib | 1 | 0 | 1 |
| Infigratinib | 1 | 0 | 1 |
| Larotrectinib | 1 | 1 | 0 |
| Lasofoxifene | 1 | 1 | 0 |
| Margetuximab | 1 | 1 | 0 |
| Metformin | 1 | 1 | 0 |
| Mocetinostat | 1 | 1 | 0 |
| Monomethyl Auristatin E | 1 | 0 | 1 |
| MTOR Inhibitor | 1 | 1 | 0 |
| Nab-paclitaxel | 1 | 0 | 1 |
| Osimertinib | 1 | 1 | 0 |
| Palbociclib Regimen | 1 | 1 | 0 |
| Panobinostat | 1 | 0 | 1 |
| Patritumab Deruxtecan | 1 | 1 | 0 |
| Pemigatinib | 1 | 1 | 0 |
| Pemrametostat | 1 | 1 | 0 |
| Pertuzumab/Trastuzumab Regimen | 1 | 0 | 1 |
| PI3Kbeta Inhibitor AZD8186 | 1 | 1 | 0 |
| PI3K/BET Inhibitor LY294002 | 1 | 1 | 0 |
| Pilaralisib | 1 | 1 | 0 |
| Pyrimidine Antagonist | 1 | 1 | 0 |
| Pyrotinib | 1 | 1 | 0 |
| Rucaparib | 1 | 1 | 0 |
| SGK1-Inh | 1 | 1 | 0 |
| Sorafenib | 1 | 1 | 0 |
| Taxane Compound | 1 | 1 | 0 |
| Temsirolimus | 1 | 1 | 0 |
| Tgx 221 | 1 | 1 | 0 |
| Trametinib | 1 | 1 | 0 |
| Trastuzumab Deruxtecan | 1 | 1 | 0 |
| Trastuzumab Deruxtecan Regimen | 1 | 1 | 0 |
| Trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| Trichostatin A | 1 | 0 | 1 |
| Triciribine | 1 | 1 | 0 |
| Tucatinib | 1 | 1 | 0 |
| Vandetanib | 1 | 1 | 0 |
| Volasertib | 1 | 1 | 0 |
| Vorinostat | 1 | 0 | 1 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.